Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Stacy Screws

Nurse Practitioner, Family Bartlett, TN Nurse Practitioner

NPI 1528120466 CMS profile 10669729

2743 Summer Oaks, Bartlett, TN 38134

Open in the dashboard

General payments

$57,765

1,027 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stacy Screws of Bartlett, TN is reported in the CMS Open Payments database as having received $57,765 across 1,027 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $19,873 193
2024 General $11,775 169
2023 General $12,465 208
2022 General $9,416 228
2021 General $4,235 229

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stacy Screws
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Stacy Screws were reported at $19,873. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Stacy Screws Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $4,235 $124 $35–$379 $132
2022 $9,416 $141 $44–$430 $149
2023 $12,465 $154 $49–$476 $160
2024 $11,775 $165 $51–$504 $164
2025 $19,873 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Insulet Corporation $21,034 89 payments
  2. Dexcom, Inc. $7,066 79 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $6,799 64 payments
  4. Lilly USA, LLC $4,824 119 payments
  5. Novo Nordisk Inc $2,803 152 payments
  6. Tandem Diabetes Care, Inc. $2,308 14 payments
  7. Abbott Laboratories $2,214 78 payments
  8. Medtronic, Inc. $1,436 21 payments
  9. Corcept Therapeutics $1,188 42 payments
  10. Mannkind Corporation $986 39 payments
  11. Other $7,109 330 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $29,806 68 payments
  2. Food and Beverage $20,235 935 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $5,100 6 payments
  4. Travel and Lodging $2,602 16 payments
  5. Education $22 2 payments
Products named General payments · program years 2021–2025
  1. Omnipod $21,034 89 payments
  2. DEXCOM G7 GSS (161) $6,230 19 payments
  3. DEXCOM STELO GLUCOSE BIOSENSOR $6,098 17 payments
  4. JARDIANCE Diabetes $5,740 21 payments
  5. JARDIANCE Diabetes $3,199 65 payments
  6. t:slim X2 Insulin Pump with Control-IQ $2,308 14 payments
  7. FreeStyle Libre 3 $1,480 46 payments
  8. Ozempic $1,365 76 payments
  9. MINIMED 780G $1,329 19 payments
  10. RYBELSUS $1,328 73 payments
  11. Other $14,947 736 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 43 drugs

Part D claims

2,082

Median for Nurse Practitioner: 389

Drug cost

$945,551

Median for Nurse Practitioner: $21,885

Branded share of claims

59.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 168 $216,302
Ozempic Semaglutide Brand 121 $158,740
Trulicity Dulaglutide Brand 76 $94,434
Jardiance Empagliflozin Brand 67 $69,765
Farxiga Dapagliflozin Propanediol Brand 71 $58,540
Rybelsus Semaglutide Brand 35 $44,837
Tresiba Flextouch U-200 Insulin Degludec Brand 37 $40,651
Tresiba Flextouch U-100 Insulin Degludec Brand 57 $37,886
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 41 $36,509
Januvia Sitagliptin Phosphate Brand 28 $29,606

The 10 drugs with the highest cost, of 43 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$95,658

Of which drugs: $393

Medicare patients

278

Average age 73

Services billed

4,720

187 women, 91 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 69%
Arthritis 51%
Ischemic heart disease 36%
Chronic kidney disease 30%
Depression 23%
Osteoporosis 18%
Heart failure 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
$6,321 67 —
Kerendia
$211 — —
Korlym
$197 — —
Wegovy
$147 — —
RECORLEV
$123 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

1,027 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record